Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05383274 · ClinicalTrials.gov registry record · Phase 4
Optilume PoST AppRoval Clinical Evaluation of Andrology ParaMeters
A Phase 4 study of Urethral Stricture, sponsored by Urotronic.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 34
- Enrollment target
- 9
- Study locations
NCT05383274 is a Phase 4 study of Urethral Stricture that is actively recruiting participants, run by Urotronic. The registered enrollment target is 34 participants. The trial reports 9 study locations across 8 states.
The verdict
NCT05383274, a Phase 4 study of Urethral Stricture, is actively recruiting participants, sponsored by Urotronic.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 34 participants
- Enrollment target
- 9
- Study locations
Study Summary
Single-arm, prospective study assessing semen quality after treatment with the Optilume Urethral DCB in men between 22 and 65 years of age.
Conditions Studied
Interventions
- COMBINATION_PRODUCT Optilume Urethral DCB
Study Locations (9)
Florida
- Orlando Health - Orlando
- Florida Urology - Tampa
Arkansas
- Arkansas Urology - Little Rock
Louisiana
- Regional Urology - Shreveport
Maryland
- Chesapeake - Hanover
Nevada
- Freedman Urology - Las Vegas
New Jersey
- New Jersey Urolgy - Millburn
New York
- Western New York - Cheektowaga
Texas
- Urology Clinics of North Texas - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2022-02-14 |
| Est. Completion | 2026-12-30 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05383274
The ClinicalTrials.gov registry entry for NCT05383274 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Urotronic, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Urethral Stricture appearing as the primary indexed condition, and to 1 intervention - of which Optilume Urethral DCB is the first listed.
NCT05383274 reports 9 study locations spanning 8 distinct geographic areas - top geographies include Florida, Arkansas, Louisiana.
Frequently Asked Questions
What is clinical trial NCT05383274 about?
NCT05383274 is a clinical study titled "Optilume PoST AppRoval Clinical Evaluation of Andrology ParaMeters". Single-arm, prospective study assessing semen quality after treatment with the Optilume Urethral DCB in men between 22 and 65 years of age.
What is the current status of trial NCT05383274?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 34 participants. The study started on 2022-02-14. Estimated completion is 2026-12-30.
What conditions does trial NCT05383274 study?
This clinical trial studies the following conditions: Urethral Stricture.
What interventions are being tested in trial NCT05383274?
The interventions under investigation include: Optilume Urethral DCB (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT05383274?
This trial is sponsored by Urotronic, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05383274 being conducted?
This trial has 9 study locations across Arkansas, Florida, Louisiana, Maryland, Nevada. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Urethral Stricture
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.